膀胱移行细胞癌中bFGF的表达及其与微血管定量的关系

目的：为了探讨膀胱移行细胞癌中碱性成纤维细胞生长因子（ｂＦＧＦ）的表达及其与血管形成定量的关系。方法：应用免疫组织化学方法,对６２例原发性膀胱移行细胞癌组织中ｂＦＧＦ进行检测,并对浸润性膀胱癌组织中微血管进行定量研究。结果：膀胱癌中ｂＦＧＦ阳性表达率为４６．８％,与病理分级、临床分期、复发及预后有关（Ｐ〈０．０５）,与浸润性癌组织中微血管定量呈正相关（Ｐ〈０．０５）,结论：ｂＦＧＦ表达对膀胱癌生物学行为有重要影响,ｂＦＧＦ是膀胱癌血管形成过程中一个主要血管生成因子,ｂＦＧＦ表达和血管形成的定量有可能成为预测膀胱癌复发、转移和预后的重要指标。     

膀胱移行细胞癌中碱性成纤维细胞生长因子表达的意义

目的 探讨膀胱移行细胞癌中碱性成纤维细胞生长因子（ｂＦＧＦ）的表达及其与临床病理指标的关系。方法 采用免疫组织化学方法，对８例正常膀胱组织及６２例原发性膀胱移行细胞癌中的ｂＦＧＦ进行检测。结果 膀胱移行细胞癌组织中ｂＦＧＦ阳性表达率为４６．８％。低分化癌和浸润性癌中的ｂＦＧＦ阳性表达率明显高于高分化癌和浅表性癌（Ｐ〈０．０５），复发者的阳性表达率明显高于未复发者（Ｐ〈０．０５），ｂＦＧＦ阳性表达者     

膀胱移行细胞癌中VEGF、bFGF及其受体的表达和临床意义

目的 探讨VEGF、bFGF及其受体在膀胱移行细胞癌中的表达和临床意义。方法 应用免疫组织化学SABC法研究65例膀胱浅表性与浸润性移行细胞癌VEGF及其受体flk,flt,bFGF及其受体flg的表达。结果 浸润性癌组VEGF及其受体、bFGF及其受体的表达显著高于非浸润性癌组（P＜0．01）。浅表性癌组中5例复发病例5项指标均呈阳性或强阳性表达。结论 5项指标的共同表达与癌组织浸润能力密切相关。浅表性膀胱移行细胞癌中VEGF及其受体、bFGF及其受体的共同表达或高表达可作为判断肿瘤早期浸润及复发倾向的参考指标。     

碱性成纤维细胞生长因子在膀胱移行细胞癌的表达及意义

目的：研究碱性成纤维细胞生长因子（ｂＦＧＦ）在膀胱移行细胞癌（ＢＴＣＣ）的表达及其意义。方法：应用免疫组化ＡＢＣ法检测３３例ＢＴＣＣ及１２例正常膀胱组织中ｂＦＧＦ抗原。结果：ｂＦＧＦ在正常移行细胞呈阴性表达，在正常组织和肿瘤组织的血管内皮细胞、平滑肌细胞均呈弱性表达，肿瘤细胞呈不同程度的阳性表达且过表达率在不同病理分级临床分期间有显著性差异（Ｐ〈０．０５），在单发与多发、初发与复发组间无显著性差异     

血管内皮生长因子、碱性成纤维细胞生长因子在非小细胞肺癌中的表达及临床意义

目的：探讨血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF)在非小细胞肺癌（Non-small cell lung cancer,NSCLC)中的表达及临床意义。方法：应用免疫组织化学方法检测96例NSCLC组织中VEGF、bFGF蛋白水平的表达，其中36例应用RT－PCR技术检测上述基因mRNA表达。结果：NSCLC中VEGF mRNA主要表达分泌性VEGF121和VEGF165，阳性率分别为69．5％（25／36）和41．7％（15／36），bFGF mRNA阳性率为52．8％（19／36）；免疫组化显示VEGF、bFGF阳性表达率分别为55．6％（20／36）和58．3％（21／36），二者之间呈正相关（P＝0．002）；VEGF、bFGF表达与患者年龄、性别、病理类型、分化程度、TNM分期、肿瘤转移、生存期等临床资料之间无统计学意义。结论：VEGF、bFGF在NSCLC血管形成中起重要作用，且二者具有协同作用。     

碱性成纤维细胞生长因子在宫颈癌中的表达及意义

目的：研究碱性成纤维细胞生长因子(bFGF)在宫颈癌组织中的表达情况，探讨其与子宫颈癌的生长、浸润及转移的关系。方法：用免疫组织化学S-P法检测42例子宫颈癌组织中及5例正常宫颈组织中bFGF的表达情况。结果：bFGF在正常子宫颈鳞状上皮细胞中呈阴性或弱阳性表达，正常组织及肿瘤组织的血管内皮细胞、平滑肌细胞均呈弱阳性表达，肿瘤细胞呈不同程度的阳性表达。bFGF强阳性表达与肿瘤大小、病理分级、临床分期、淋巴结有无转移均有显著相关性(P＜0．05)。结论：bFGF在子宫颈癌组织中的表达与肿瘤的生长、浸润及转移密切相关，可作为反映子宫颈癌生物学行为的指标之一。     

碱性成纤维细胞生长因子在前列腺癌中的表达

目的探讨碱性成纤维细胞生长因子(bFGF)在前列腺癌中表达的临床意义。方法应用半定量RT-PCR技术和免疫组织化学方法,检测22例前列腺癌组织中bFGF的表达,并与正常的前列腺组织进行比较。结果前列腺癌组织中的bFGF表达高于正常的前列腺组织(P<0.05);bFGF表达升高的程度与前列腺癌病理分级和临床分期均无明显关系。结论前列腺癌组织中bFGF的表达高于正常前列腺组织,提示bF-GF与前列腺癌的发生发展密切相关。     

VEGF和 bFGF在浅表膀胱移行细胞癌中的表达及意义

背景与目的：血管内皮生长因子（vascular endothelial growth factor,VEGF)和碱性成纤维细胞生长因子（basic fibroblast growth factior,bFGF)都能促进血管内皮细胞分裂和诱导血管形成,是肿瘤的生长,浸润,和转移过程中非常重要的物质,但它们在单发性和多发性浅表膀胱移行细胞癌中表达的差异则未见报道,本研究主要是探讨VEGF和bFGF在浅表膀胱移行细胞癌中的表达及意义。方法：采用免疫组化法对60例浅表膀胱移行细胞癌组织及10例正常膀胱组织进行VEGF和bFGF的检测,观察单发性和多发性浅表膀胱移行细胞癌组织中VEGF和bFGF表达的关系。结果：多发性浅表膀胱移行细胞癌的VEGF阳性率为55.6%,bFGF阳性率为50.0%,以及VEGF和bFGF共同表达阳性率为50.0%。均明显高于单发者的水平,而高水平表达的多发性肿瘤患者的术后复发率61.1%也明显高于单发组的复发率（单发组的复发率16.7%)。结论：VEGF和bFGF表达水平的高低与浅表膀胱移行细胞癌的生物学行为有关。     

碱性成纤维细胞生长因子与肿瘤

碱性成纤维细胞生长因子（bFGF)作为一种细胞丝裂原和促血管生成因子，在许多肿瘤的生长中起着重要的作用，许多实验研究提示肿瘤组织或患者体液中的bFGF水平能作为诊断或判断预后的指标，目前，阻止bFGF产生及抑其生物学活性的发挥，作为一种有效的抗肿瘤策略已得到广泛的发展，具有良好的应用前景。     

碱性成纤维细胞生长因子与肿瘤

碱性成纤维细胞生长因子(bFGF)作为一种细胞丝裂原和促血管生成因子,在许多肿瘤的生长中起着重要的作用.许多实验研究提示肿瘤组织或患者体液中的bFGF水平能作为诊断或判断预后的指标.目前,阻止bFGF产生及抑制其生物学活性的发挥,作为一种有效的抗肿瘤策略已得到广泛的发展,具有良好的应用前景.     

Coexisting leiomyosarcoma and transitional cell carcinoma of the urinary bladder

A rare case of coexisting sarcoma and carcinoma of the urinary bladder is reported and the literature is reviewed. Because of the differences in the histogenesis and prognosis, such cases should be differentiated from cases of carcinosarcoma of the urinary bladder.     

Metachronous bladder tumors in patients with upper urinary tract transitional cell carcinoma

Sixty-nine patients who underwent nephroureterectomy for upper urinary tract transitional cell carcinoma were included in the study. The following data were collected for each patient: grade and stage of renal/ureteral tumor, tumor location, timing of tumor appearance and recurrence in the bladder, grade and stage of each of the recurrent tumors, and number of recurrences. Follow-up ranged between 2 and 15 years. Thirty-three patients (47.8%) developed metachronous bladder tumors. The appearance of the bladder tumors was related to tumor grade and multifocality of the upper urinary tract TCC. Of the 33 patients, 19 had 1 tumor appearance in the bladder, 6 had 2 recurrences, and 8 had 3 recurrences. The 5-year survival rate for patients with no subsequent bladder tumors was 57% compared to 22% for those who had subsequent tumors. It is concluded that the appearance of bladder tumors following nephroureterectomy characterizes a group of patients with biologically more active disease with unfavorable prognosis. © 1994 Wiley-Liss, inc.     

The significance of ureteral obstruction in lnvasive transitional cell carcinoma of the urinary bladder

Ureteral obstruction is a frequent complication of transitional cell carcinoma (TCC), known as a poor prognostic sign and indicative of advanced disease. We investigated retrospectively the medical records of 122 consecutive patients who suffered from invasive TCC of the urinary bladder during a 6-year period. Unilateral or bilateral ureteral obstruction was found in 66 patients (54.1%). High stage (T3-T4) and grade (III-IV) tumors were correlated with ureteral obstruction in 89.4% and 83.3% respectively compared to 67.9% and 66.1%, respectively, among patients with normal upper tracts (P < 0.001); 10.6% of the patients with ureteral obstruction had low stage disease, and all of them proved to have involvement of the ureteral orifices on the affected side. The 5-year survival rate of patients with and without ureteral obstruction was 32.2% and 65.9%, respectively (P < 0.001). The presence of ureteral obstruction, particularly in the absence of intravesical involvement of the ureteral orifices, signified a high stage, muscle invasive, and often metastatic tumor in more than 90% of the patients. Ureteral obstruction was an accurate criterion for poor prognostic and was associated with significantly lower, overall and stage-specific, survival rates, despite of radical surgery. We conclude that evidence of ureteral obstruction is an important staging standard and significant prognostic indicator in transitional cell carcinoma of the urinary bladder. © 1993 Wiley-Liss, Inc.     

纤维粘连蛋白在膀胱移行细胞癌中的表达

本文应用ＡＢＣ免疫组织化学方法对４９例膀胱移行细胞癌中的纤维粘连蛋白（ＦＮ）作了研究。结果发现：ＦＮ的分布形式有细胞周、间质及细胞浆三种形式：随着移行细胞癌组织学分级的增高，细胞周ＦＮ及间质ＦＮ逐渐减少，而胞浆ＦＮ则有所增加。结果提示：这些变化可能是膀胱移行细胞癌浸润转移的重要基础；并可能与预后有一定关系。     

PTEN与FHIT在膀胱移行细胞癌中的表达及其临床意义

目的：探讨PTEN与FHIT在膀胱移行细胞癌（bladder transitional cell carcinoma,BTCC）组织中的表达及其临床意义。方法：应用免疫组化技术（SP法）检测62例膀胱移行细胞癌和13例正常膀胱黏膜标本中PTEN与FHIT蛋白的表达情况。结果：PTEN、FHIT蛋白在BTCC表达率分别为56.5%和51.6%,明显低于二者在正常膀胱黏膜中的表达,差异有统计学意义（P〈0.05）;在BTCC中PTEN与FHIT蛋白表达均与肿瘤病理分级和分期密切相关（P〈0.05）,在BTCC标本中PTEN蛋白表达与FHIT蛋白表达呈正相关（r=0.448,P〈0.05）。结论：PTEN、FHIT在BTCC的发生、发展中发挥了重要作用。PTEN、FHIT联合检测可作为预测BTCC生物学行为和预后判断的重要指标。     

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Background: The possibility of bladder preservation as well as the utility of neo-adjuvant chemotherapy for invasive bladder cancer are controversial issues. The purpose of this study was the evaluation of neo-adjuvant M-VAC chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder.Patients and methods: Eighty-seven consecutive evaluable patients with T₂–T_4aN_xM₀ TCC of the bladder were treated with three cycles of neo-adjuvant M-VAC chemotherapy. After three cycles of M-VAC, 42 patients had TURB alone, 13 patients underwent partial cystectomy, and 32 patients were to undergo radical cystectomy.Results: Forty (51%) patients were T₀ at the TURB following M-VAC. Thirty (71%) patients who had chemotherapy and TURB alone are alive; at a median follow-up of 54+ months (8+–109+). Twenty-four (57%) have maintained an intact bladder. Of 13 responding patients with monofocal lesions who underwent partial cystectomy, 8 patients (62%) are alive with a functioning bladder, at a median follow-up of 80+ months (16–107+ months). At a follow-up of 32 months (7–121+ months), 20 (63%) patients in the radical cystectomy group are alive. In patients who had downstaging to T₀ or superficial disease, median follow-up is 55 months (10–121+ months) and five-year survival is 71%. Patients who failed to respond (T₂ or greater after chemotherapy), at a median follow-up of 24 months (7–103+ months), had five-year survival of only 29%.Conclusions: Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials.     

环氧化酶-2 mRNA在膀胱癌中的表达及意义

目的 :探讨环氧化酶 -2 (COX 2 )mR NA在膀胱移行细胞癌 (TCCB)组织中的表达及其意义。方法 :采用RT PCR方法检测 78例TCCB组织中COX 2的表达 ,16例正常黏膜作为对照。结果 :16例正常组织无COX 2表达。COX 2表达阳性率为 3 5 9% ( 2 8/78) ,COX 2表达与TCCB分级、分期之间呈正相关 ,P <0 0 5。COX 2的表达在复发者中的表达率高于未复发者 ,P <0 0 5。COX 2的表达在转移者中的表达率高于未转移者 ,P <0 0 5。结论 :COX 2在TCCB的发生发展中起重要的正性调节因子的作用。COX 2与TCCB的恶性程度和进展恶化有关。COX 2可作为判断TCCB预后的指标。     

脂肪酸合成酶在膀胱移行细胞癌组织中的表达及其临床意义

背景与目的：脂肪酸合成酶（fatty acid synthase,FAS）是一种新的肿瘤标志物,高表达常提示肿瘤的预后不良,由此本文旨在研究膀胱移行细胞癌中的表达及其临床意义.方法：对65例随访5年的膀胱移行细胞癌手术患者的石蜡标本进行FAS的免疫组织化学染色分析,并与15例正常膀胱粘膜组织进行对照.结果：与正常组织相比,FAS在膀胱移行细胞癌组织中高表达,阳性表达率58.5%（38/65）,差异有显著性（P＜0.05）.FAS的表达与肿瘤分级、初发、复发有关（P＜0.05）,但与临床分期及肿瘤数目无关.FAS阳性表达患者的5年生存率远低于阴性患者（18% vs.44%）,差异有显著性（P＜0.05）.结论：FAS在膀胱移行细胞癌组织中表达增高,酶活性增强;FAS在膀胱移行细胞癌组织中表达增高有提示不良预后的作用.     

Ezrin、CD44在膀胱移行细胞癌的表达与意义

目的：探讨ezrin、CD44在膀胱移行细胞癌（BTCC）中的表达与意义。方法：采用免疫组织化学检测60例膀胱移行细胞癌与14例正常膀胱组织中ezrin、CD44的蛋白表达。结果：ezrin、CD44在膀胱移行细胞癌组织中的蛋白表达明显高于正常膀胱组织（P〈0.05）,ezrin、CD44的蛋白表达与膀胱移行细胞癌组织的病理分级、临床分期密切相关,ezrin、CD44蛋白表达的阳性表达随着膀胱肿瘤病理分级、临床分期的增高而增高（P〈0.05）。ezrin、CD44的蛋白表达在膀胱移形细胞癌中有相关性。结论：ezrin、CD44在BTCC发生、发展过程中起重要作用。Ezrin、CD44在膀胱移形细胞癌的发生、进展中可能有协同性。ezrin可作为诊断、判断预后、指导治疗、随访检测的指标。